Compare LINC & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LINC | MGTX |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 813.3M | 881.7M |
| IPO Year | 2005 | 2018 |
| Metric | LINC | MGTX |
|---|---|---|
| Price | $20.45 | $9.47 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $47.40 | $27.75 |
| AVG Volume (30 Days) | 587.9K | ★ 737.1K |
| Earning Date | 11-09-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | 33.02 |
| EPS | 0.20 | ★ 1.30 |
| Revenue | ★ $261,853,000.00 | $81,391,000.00 |
| Revenue This Year | $14.61 | $314.19 |
| Revenue Next Year | $9.09 | N/A |
| P/E Ratio | $101.05 | ★ $7.22 |
| Revenue Growth | 32.98 | ★ 144.57 |
| 52 Week Low | $17.29 | $6.62 |
| 52 Week High | $56.34 | $15.35 |
| Indicator | LINC | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.02 | 37.53 |
| Support Level | N/A | $8.88 |
| Resistance Level | $26.18 | $10.11 |
| Average True Range (ATR) | 0.94 | 0.46 |
| MACD | -0.02 | 0.08 |
| Stochastic Oscillator | 17.53 | 27.12 |
Lincoln Educational Services Corp provides diversified career-oriented post-secondary education to high school graduates and working adults. The company offers programs in automotive technology, skilled trades, healthcare services, hospitality services, and business and information technology. Its reportable segments include: Campus Operations and Transitional. The majority of the revenue is generated from the Campus Operations segment, which includes all campuses that are continuing in operation and contribute to the company's core operations and performance.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.